Jason Karlawish of the Perelman School of Medicine weighed in on revised FDA guidance on a new Alzheimer’s drug and calls for an investigation into its approval and price. “This event only adds to the importance of having those congressional hearings to figure out what’s going on at F.D.A. and why they’re doing this,” he said.

July 8, 2021 ・ From The New York Times